← back to search

Davide María Donati

Leiden University Medical Center · IT
Area of research
Pulmonary and Respiratory Medicine · Rheumatology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Bone Tumor Diagnosis and Treatments, Management of metastatic bone disease, and Orthopaedic implants and arthroplasty.
h-index
68
citations
15,828
works
562
NIH funding
primary concept
Medicine
email

Recent publications

3D-Printed Cut Guides and Custom Prostheses for Pelvic Reconstruction in Bone Sarcoma Patients: Complications, Survival Rates, and Functional Outcomes.
2026cited by 1position: contributordoi
Can We Develop a Web-based Nomogram That Could Predict the Risk of Local Recurrence After Treatment for Giant Cell Tumor of Bone of the Extremities by Curettage?
2026cited by 0position: contributordoi
The functional recovery trajectory in patients undergoing lower limb salvage surgery for bone tumour: an observational study.
2026cited by 0position: contributordoi
Hip Hemi‐Resurfacing With 3D‐Printed Titanium Mini‐Prosthesis: A Case Report
Case Reports in Orthopedics 2026cited by 0position: contributordoi
Two-stage revision for infection of oncological megaprostheses
The Bone & Joint Journal 2025cited by 10position: middledoi
Two-stage revision for infection of oncological megaprostheses : a multicentre EMSOS study.
2025cited by 7position: contributordoi
Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
Clinical Cancer Research 2025cited by 4position: middledoi
Comparison of histological response across patients with Ewing sarcoma treated with preoperative chemotherapy with or without preoperative radiotherapy.
2025cited by 3position: contributordoi
Is Proximal Femur Reconstruction With a Vascularized Fibula and Allograft Successful at Reconstructing a Tumor Resection in Children 6 Years of Age or Younger?
2025cited by 3position: contributordoi
What Are the Complications, Reconstruction Survival, and Functional Outcomes of Modular Prosthesis and Allograft-prosthesis Composite for Proximal Femur Reconstruction in Children With Primary Bone Tumors?
2025cited by 3position: contributordoi
Osteosarcoma and Ewing Sarcoma of Bone: An Italian Mono-Institutional Epidemiological Study.
2025cited by 3position: contributordoi
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
2025cited by 2position: contributordoi
Insights into the osteosarcoma microenvironment: Multiscale analysis of structural and mineral heterogeneity.
2025cited by 2position: contributordoi
Blinded prediction of custom-made pelvic implant failure using patient-specific finite element modeling.
2025cited by 1position: contributordoi
Tumor Immune Microenvironment-Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial.
2025cited by 1position: contributordoi
Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial.
2025cited by 1position: contributordoi
Strengthening football: The role of the nordic hamstring exercise in preventing hamstring injuries.
2025cited by 0position: contributordoi
Genomic Profiling of Highly Aggressive Musculoskeletal Sarcomas Identifies Potential Therapeutic Targets: A Single-Center Experience.
2025cited by 0position: contributordoi
Establishment and Characterization of OS-MET-R-092: A Novel Patient-Derived Cell Culture from an Osteosarcoma Bone Metastasis.
2025cited by 0position: contributordoi
Supplementary Figure S6 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S3 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S4 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S5 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S1 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Data from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Table S1 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S2 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Table S2 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Table S3 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi
Supplementary Figure S7 from Tumor Immune Microenvironment–Associated Prognostic and Mifamurtide-Response Gene Signatures for Localized Osteosarcoma: A Correlative Study of the ISG/OS-2 Trial
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 22 papers (2020–2026)Emanuela Palmerini · Istituto Ortopedico Rizzoli19 papers (2019–2025)Marco Gambarotti · Hospital Universitario Fundación Jiménez Díaz13 papers (2019–2025)Katia Scotlandi · Istituti di Ricovero e Cura a Carattere Scientifico12 papers (2019–2025) · 12 papers (2019–2025)Alberto Righi · Azienda-Unita' Sanitaria Locale Di Cesena11 papers (2019–2024)D.A. Campanacci · Azienda Ospedaliero-Universitaria Careggi11 papers (2019–2025)Angelo Paolo Dei Tos · University of Padua9 papers (2019–2025)Andreas F. Mavrogenis · Physiotherapy New Zealand9 papers (2019–2024)Silvia Stacchiotti · Dana-Farber Cancer Institute9 papers (2020–2025)Costantino Errani · Memorial Sloan Kettering Cancer Center7 papers (2021–2026)Shinji Tsukamoto · MDPI7 papers (2019–2024) · 7 papers (2019–2024)Luca Cevolani · MDPI6 papers (2021–2026)Javier Martín‐Broto · University of Miami6 papers (2020–2024)Paolo G. Casali · Fondazione IRCCS Istituto Nazionale dei Tumori6 papers (2020–2025)Alessandra Longhi · Istituto Ortopedico Rizzoli6 papers (2017–2022)Giovanni Grignani · Hospital Universitario Fundación Jiménez Díaz6 papers (2017–2024)Toni Ibrahim · Media Working Group5 papers (2022–2025) · 4 papers (2021–2025)